4teen4.de - Start - 4TEEN4 Pharmaceuticals GmbH

Description: At 4TEEN4, we are tackling a high and unmet medical need in the intensive care units worldwide.

innovation (7729) investment (5995) antibody (179) critical care (145) heart failure (71) precision medicine (55) biomarker (41) sepsis (36) unmet need (1) cardiogenic shock (1)

Example domain paragraphs

Supported by The project is funded by the European Social Fund (ESF) and the Federal State of Brandenburg via the Brandeburg Ministry for Labor, Social Affairs, Health, Women and Family (MASGF).

Dipeptidyl Peptidase 3 is an important causative pathway in septic and cardiogenic shock

read more We are developing a targeted therapy to inhibit DPP3 Procizumab will be a first-in-class antibody targeting the DPP3 pathway in septic & cardiogenic shock.